Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $150.00, for a total value of $150,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Bruce C. Cozadd also recently made the following trade(s):

  • On Tuesday, September 12th, Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals PLC stock. The shares were sold at an average price of $153.52, for a total value of $153,520.00.

Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded up 0.52% during mid-day trading on Wednesday, reaching $150.39. The company had a trading volume of 256,799 shares. The stock has a market capitalization of $9.03 billion, a price-to-earnings ratio of 23.17 and a beta of 1.05. Jazz Pharmaceuticals PLC has a 52-week low of $95.80 and a 52-week high of $163.75. The company’s 50 day moving average is $148.60 and its 200 day moving average is $151.49.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.85 by ($0.13). Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The firm had revenue of $394.39 million during the quarter, compared to the consensus estimate of $410.83 million. During the same quarter last year, the firm posted $2.67 EPS. The business’s revenue was up 3.5% on a year-over-year basis. Equities analysts predict that Jazz Pharmaceuticals PLC will post $10.88 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Bruce C. Cozadd Sells 1,000 Shares of Jazz Pharmaceuticals PLC (JAZZ) Stock” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/04/bruce-c-cozadd-sells-1000-shares-of-jazz-pharmaceuticals-plc-jazz-stock.html.

Several large investors have recently bought and sold shares of JAZZ. BlackRock Inc. raised its stake in shares of Jazz Pharmaceuticals PLC by 3,163.9% in the first quarter. BlackRock Inc. now owns 3,215,159 shares of the specialty pharmaceutical company’s stock valued at $466,615,000 after acquiring an additional 3,116,652 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Jazz Pharmaceuticals PLC by 11,990.7% in the second quarter. Janus Henderson Group PLC now owns 873,919 shares of the specialty pharmaceutical company’s stock valued at $135,894,000 after acquiring an additional 866,691 shares during the last quarter. FMR LLC raised its stake in shares of Jazz Pharmaceuticals PLC by 11.4% in the second quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock valued at $1,289,159,000 after acquiring an additional 849,348 shares during the last quarter. Janus Capital Management LLC raised its stake in shares of Jazz Pharmaceuticals PLC by 46.8% in the first quarter. Janus Capital Management LLC now owns 1,470,245 shares of the specialty pharmaceutical company’s stock valued at $213,367,000 after acquiring an additional 468,940 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Jazz Pharmaceuticals PLC by 41.2% in the second quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock valued at $218,540,000 after acquiring an additional 410,031 shares during the last quarter. Institutional investors own 88.34% of the company’s stock.

Several analysts have issued reports on JAZZ shares. Leerink Swann upped their price objective on Jazz Pharmaceuticals PLC from $169.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, July 4th. Janney Montgomery Scott upped their price objective on Jazz Pharmaceuticals PLC from $138.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, July 4th. Deutsche Bank AG restated a “buy” rating and set a $176.00 price objective on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, July 4th. Vetr upgraded Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $165.11 price objective on the stock in a research note on Tuesday, June 27th. Finally, Royal Bank Of Canada set a $210.00 price objective on Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Tuesday, June 27th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eighteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $180.91.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.